Clinical Trial Update: Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and effects of saracatinib (AZD0530) in breast and prostate cancer subjects with metastatic bone disease; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer
• Prostate Cancer

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-06-27